CA
NZ
UK
AU
IND
US
…
Harvard Apparatus Regenerative Technology Inc., a clinical-stage biotechnology company, focuses on developing regenerative-medicine treatments for disorders of the gastro-intestinal system and other organs resulting from cancer, trauma, or birth defects. The company's lead product candidate is Cellspan Esophageal Implant for the treatment of severe esophageal disease. It's pipeline includes organ-regeneration technology for the repair or replacement of diseased or damaged organs; and product candidates to treat conditions of the esophagus, including traumatic injury, caustic burns, tissue damage following chemoradiation therapy, birth defects, and reconstruction of the colon and uterus wound repair. The company also sells consumer health products that focuses on personal healthcare, including dietary supplements. Harvard Apparatus Regenerative Technology Inc. was formerly known as Biostage, Inc. and changed its name to Harvard Apparatus Regenerative Technology Inc. in July 2023. The company was founded in 2009 and is headquartered in Holliston, Massachusetts.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Harvard Apparatus Regenerative Technology Inc. is an OTCQB-listed company that identifies itself as developing regenerative medicine technologies; public information about the company is limited. Major long-term growth drivers could include broader adoption of regenerative therapies and successful translation of its technologies into commercial products or licensing arrangements. Investors may find exposure to the regenerative-medicine sector attractive if the company advances development or secures partnerships that reduce commercialization risk.
Principal investment risks include early-stage and unproven technology with substantial clinical and regulatory hurdles, likely need for external financing and shareholder dilution, and thin OTC trading liquidity that could increase price volatility.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -6.87M | -7.73M | -8.95M | -6.07M | -7.98M |
| Net income | -6.87M | -7.73M | -8.95M | -6.07M | -7.98M |
| Selling general administrative | 4.32M | 5.58M | 6.01M | 4.41M | 7.04M |
| Gross profit | 0.06M | 0.16M | 0.08M | 0.00M | - |
| Reconciled depreciation | 0.10M | 0.17M | 0.13M | 0.05M | 0.11M |
| Ebit | - | - | - | - | -8.64M |
| Ebitda | - | - | - | -6.10M | -8.47M |
| Operating income | -6.92M | -7.73M | -8.99M | -6.15M | -8.47M |
| Interest expense | 0.01M | 0.04M | 0.01M | - | - |
| Interest income | 0.04M | 0.03M | 0.06M | - | - |
| Net interest income | 0.03M | -0.01M | 0.05M | - | - |
| Total revenue | 0.70M | 0.43M | 0.10M | 0.00M | 0.00M |
| Total operating expenses | 7.62M | 8.16M | 9.09M | 6.15M | 8.47M |
| Cost of revenue | 0.65M | 0.27M | 0.02M | - | - |
| Total other income expense net | 0.02M | - | -0.01M | 0.08M | 0.49M |
| Net income from continuing ops | -6.87M | -7.73M | -8.95M | -6.07M | -7.98M |
| Net income applicable to common shares | - | - | - | - | -7.98M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 2.68M | 4.44M | 2.61M | 2.40M | 1.87M |
| Other current assets | 0.19M | 0.26M | 0.01M | 0.05M | 0.06M |
| Total liab | 1.62M | 1.22M | 0.97M | 1.41M | 4.89M |
| Total stockholder equity | 1.06M | 3.22M | 1.65M | 0.99M | -3.03M |
| Other current liab | - | - | 0.00M | 0.01M | 3.25M |
| Common stock | - | - | - | - | 0.11M |
| Capital stock | 0.18M | 0.16M | 0.14M | 4.30M | 0.11M |
| Retained earnings | -106.56M | -99.69M | -91.96M | -83.01M | -76.94M |
| Cash | 1.35M | 2.49M | 0.43M | 1.24M | 1.24M |
| Total current liabilities | 1.53M | 1.02M | 0.97M | 1.36M | 4.84M |
| Property plant equipment | - | - | - | - | 0.28M |
| Total current assets | 1.83M | 3.23M | 0.78M | 1.59M | 1.59M |
| Net tangible assets | - | - | - | - | -3.03M |
| Net receivables | 0.02M | 0.23M | 0.00M | - | - |
| Inventory | 0.02M | 0.08M | 0.05M | - | - |
| Accounts payable | 0.45M | 0.45M | 0.45M | 0.68M | 0.68M |
| Non currrent assets other | - | - | - | - | 0.57M |
| Non current assets total | 0.85M | 1.21M | 1.83M | 0.81M | 0.57M |
| Capital lease obligations | 0.20M | 0.29M | 0.05M | 0.15M | 0.17M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | 0.00M | 0.00M | -0.01M | 0.00M |
| Change to liabilities | - | - | - | 0.00M | 0.65M |
| Net borrowings | 0.00M | 0.00M | 0.00M | - | - |
| Total cash from financing activities | 2.70M | 6.91M | 6.14M | 5.06M | 2.84M |
| Change to operating activities | - | - | - | - | 4.04M |
| Net income | -6.87M | -7.73M | -8.95M | -6.07M | -7.98M |
| Change in cash | -1.13M | 2.05M | -0.81M | -0.05M | 0.22M |
| Begin period cash flow | 2.49M | 0.43M | 1.24M | 1.29M | 1.08M |
| End period cash flow | 1.35M | 2.49M | 0.43M | 1.24M | 1.29M |
| Total cash from operating activities | -3.83M | -4.85M | -6.94M | -5.11M | -2.63M |
| Issuance of capital stock | 2.70M | 6.48M | 5.99M | 5.06M | 2.84M |
| Depreciation | 0.10M | 0.17M | 0.13M | 0.05M | 0.11M |
| Change to inventory | 0.06M | -0.03M | -0.05M | - | - |
| Change to account receivables | 0.21M | -0.23M | -0.00M | - | - |
| Sale purchase of stock | - | - | - | - | 0.00M |
| Change to netincome | - | - | - | 0.42M | 0.56M |
| Capital expenditures | 0.00M | 0.00M | 0.01M | 0.01M | 0.00M |
| Change in working capital | 0.93M | 0.31M | -1.59M | -0.11M | 4.69M |
| Stock based compensation | 2.01M | 2.40M | 3.46M | 1.03M | 0.98M |
| Free cash flow | -3.83M | -4.85M | -6.95M | -5.11M | -2.63M |
Sector: Consumer Defensive Industry: Packaged Foods
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| HRGN Harvard Apparatus Regenerative Technology Inc. |
- -% |
1.81 | - | - | 47.51 | 267.53 | 35.39 | -7.27 |
| NSRGF Nestle SA |
- -% |
101.69 | 26.86 | 18.76 | 3.13 | 7.10 | 3.81 | 21.70 |
| NSRGY Nestle SA ADR |
0.07 0.07% |
103.51 | 26.82 | 18.66 | 3.18 | 7.07 | 3.81 | 21.70 |
| DANOY Danone PK |
0.23 1.52% |
15.40 | 24.23 | 17.64 | 1.88 | 2.57 | 1.88 | 11.70 |
| GPDNF Danone S.A |
- -% |
75.00 | 20.30 | 14.75 | 1.65 | 2.24 | 1.76 | 10.92 |
Harvard Apparatus Regenerative Technology Inc., a clinical-stage biotechnology company, focuses on developing regenerative-medicine treatments for disorders of the gastro-intestinal system and other organs resulting from cancer, trauma, or birth defects. The company's lead product candidate is Cellspan Esophageal Implant for the treatment of severe esophageal disease. It's pipeline includes organ-regeneration technology for the repair or replacement of diseased or damaged organs; and product candidates to treat conditions of the esophagus, including traumatic injury, caustic burns, tissue damage following chemoradiation therapy, birth defects, and reconstruction of the colon and uterus wound repair. The company also sells consumer health products that focuses on personal healthcare, including dietary supplements. Harvard Apparatus Regenerative Technology Inc. was formerly known as Biostage, Inc. and changed its name to Harvard Apparatus Regenerative Technology Inc. in July 2023. The company was founded in 2009 and is headquartered in Holliston, Massachusetts.
| Name | Title | Year Born |
|---|---|---|
| Mr. Junli He C.F.A. | CEO & Chairman | 1974 |
| Mr. Yu Hong B.S., C.F.A., M.S. | President | 1973 |
| Mr. Joseph L. Damasio Jr. | Chief Financial Officer | 1974 |
| Dr. William L. Fodor Ph.D. | Chief Scientific Officer | 1959 |
| Dr. Shunfu Hu Ph.D. | Corporate Secretary | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.40%
Communication Services
-0.45%
Consumer Cyclical
-0.55%
Consumer Defensive
-0.01%
Energy
-0.01%
Financial Services
-0.40%
Financials
-0.15%
Healthcare
-1.15%
Industrials
-0.46%
Real Estate
-0.29%
Technology
-1.22%
Utilities
-0.10%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
+0.55%
Please wait processing your request...